SCHEMBL18069727

SCHEMBL18069727

CC(C)C1CC(O)CC(C(C)C)C1

nearest known ligand 0.43

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.43
CYP2C9 P11712 1/20 0.43
TRPA1 O75762 2/20 0.32
TRPM8 Q7Z2W7 2/20 0.32
PIK3CD O00329 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6757990 0.97
SCHEMBL6757981 0.97
SCHEMBL679519 0.97
SCHEMBL14367741 0.94 LMNA (0.38) LMNACYP2C9TRPA1TRPM8PIK3CD
SCHEMBL10297514 0.84 TRPA1 (0.37) LMNACYP2C9TRPA1TRPM8
SCHEMBL1270382 0.83 NOS3 (0.33)
SCHEMBL22243252 0.82 LMNA (0.35) LMNACYP2C9TRPA1TRPM8
SCHEMBL26685140 0.82 LMNA (0.35) LMNACYP2C9TRPA1TRPM8
SCHEMBL10409614 0.80 DPP4 (0.40) LMNACYP2C9TRPA1TRPM8
SCHEMBL7751563 0.80 TRPA1 (0.40) TRPA1TRPM8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023086539-A2 BCAT2 INHIBITORS AGIOS PHARMACEUTICALS, INC. (US) 2023-05-19 WO disclosed
US-10570388-B2 Phosphate replacement MRNA cap analogs MODERNATX, INC. (US) 2020-02-25 US disclosed
US-10563195-B2 Phosphate replacement mRNA cap analogs MODERNATX, INC. (US) 2020-02-18 US disclosed
US-10428106-B2 Phosphate replacement mRNA cap analogs MODERNATX, INC. (US) 2019-10-01 US disclosed
US-20160264554-A1 POLYCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) DANA-FARBER CANCER INSTITUTE, INC. 2016-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10428106-B2 Phosphate replacement mRNA cap analogs RNGTT, RNMT, CPSF6 LMNA 3740/4885CYP2C9 4677/4885TRPA1 4843/4885
US-10570388-B2 Phosphate replacement MRNA cap analogs RNGTT, RNMT, CPSF6 LMNA 3607/4885CYP2C9 4655/4885TRPA1 4851/4885
US-20160264554-A1 POLYCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) CDK13, CDK3, CDK12 LMNA 1208/4885CYP2C9 1056/4885TRPA1 4524/4885
US-10563195-B2 Phosphate replacement mRNA cap analogs RNGTT, RNMT, CPSF6 LMNA 3607/4885CYP2C9 4655/4885TRPA1 4851/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.